B001 not checked
Shanghai Jiaolian Drug Research and Development Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The subjects will receive IV dose of B001 on Day 1 and Day 15 of RCP”In the company’s words, NCT06413654 on ClinicalTrials.gov
- Tested for
- Neuromyelitis Optica Spectrum Disorders
- Main trialPhase 2/3
- “To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.”In the company’s words, NCT06413654 on ClinicalTrials.gov
Other drugs for Neuromyelitis Optica Spectrum Disorders
- EculizumabAlexion Pharmaceuticals, Inc. · Phase 3
- SatralizumabRoche · Phase 3
- RavulizumabAlexion Pharmaceuticals, Inc. · Phase 3
- DivozilimabBiocad · Phase 3
- MIL62Beijing Mabworks Biotech Co., Ltd. · Phase 3
- CTX112CRISPR Therapeutics · Phase 1/2
Coming up1
- 31 Oct 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 31 Oct 2027 | A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026